Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
**Background:** Clostridium difficile is associated with 20–30% of cases of antibiotic-associated diarrhoea. The incidence of C. difficile infection (CDI) is higher in Ireland than in other countries in Europe, and it is associated with considerable morbidity. Previously recommended standard therape...
Saved in:
Main Authors: | Anke van Engen, Montserrat Casamayor, Fidelma Loftus, Martin Coen, Andy Garnham, Maureen Watt, Larry Lacey |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2015-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9903 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
by: George G Zhanel, et al.
Published: (2015-01-01) -
Clinical and Economic Consequences of Vancomycin and Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada
by: Monika Wagner, et al.
Published: (2014-01-01) -
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
by: Thomas Louie, et al.
Published: (2015-12-01) -
Clostridium difficile Outbreaks
by: Paul Bayardelle
Published: (2007-01-01) -
Empyema Caused by Clostridium difficile
by: Darren A Hudson, et al.
Published: (1999-01-01)